Close Menu

ER/PgR

A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors. 

At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.

Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.

The investigators used gene expression, chromatin interaction, and functional annotations to prioritize 191 genes as targets of potentially causal variants.

With targeted gene sequencing data from a large set of archived tumor samples, researchers identified somatic mutations coinciding with better or worse overall survival.

CAP and ASCO issued new guidelines to improve accuracy of immunohistochemistry-based ER and PgR testing in breast cancer. The groups estimate that between 10 percent and 20 percent of IHC test results throughout the world may be inaccurate, yielding false-positive or false-negative results.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.